Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 16

  • 357 clinical trials
  • 141 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis14Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

357 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

357 clinical trials

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Safety, Tolerability and Pharmacokinetics of MK-7480 and Diltiazem Hydrochloride in Healthy Adult Male Participants for Non‑alcoholic Steatohepatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Diltiazem Hydrochloride
  • Sponsor:Merck Sharp & Dohme LLC

Hepatic function abnormal

Not recruiting

Effect of moderate or severe liver impairment on the pharmacokinetics, safety and tolerability of camizestrant in post‑menopausal women

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Hepatic function abnormal

Not recruiting

Phase 1 Study of REN001 Single‑Dose Pharmacokinetics in Adults with Normal, Mild, Moderate, or Severe Liver Impairment

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Reneo Pharmaceuticals Inc.

Hepatic function abnormal

Not recruiting

Pharmacokinetic Study of Oral TVB-2640 in Adults with Mild, Moderate, or Severe Hepatic Impairment and in Healthy Volunteers

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Sagimet Biosciences Inc.

Hepatitis D

Not recruiting

A Study of Brelovitug Compared to Delayed Treatment in Patients with Chronic Hepatitis Delta Infection

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bjt-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Chronic hepatitis B

Not recruiting

Study of GSK3965193 and Bepirovirsen for People Living with Chronic Hepatitis B Infection and Healthy Participants

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Alcoholic liver disease

Not recruiting

A study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Endometrial cancer+2

Not recruiting

A study comparing how lenvatinib capsules are absorbed in the body in healthy volunteers under fasting and fed conditions

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Lenvatinib
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Hepatic fibrosis+1

Not recruiting

Study comparing how the body processes GB1211 capsule and tablet forms with and without food in healthy volunteers

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:2-(5-BROMOPYRIDIN-3-YL)SULFANYL-6-(HYDROXYMETHYL)-4-[4-(3,4,5-TRIFLUOROPHENYL)TRIAZOL-1-YL]OXANE-3,5-DIOL
  • Sponsor:Galecto Biotech AB

Metabolic dysfunction-associated liver disease+2

Not recruiting

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Opella Healthcare Group S.A.S.

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Porphyria non-acute

Not recruiting

Study of bitopertin to improve sunlight tolerance in adults with erythropoietic protoporphyria or X-linked protoporphyria

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Disc Medicine Inc.

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.